Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table

Gilead Sciences is no stranger to legal claims surrounding its market-leading HIV franchise. Now, the company and two other major biopharma players are heading to trial over claims they worked together to restrict competition in the marketplace.